Top

Published in:

01-09-2010 | Review

Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis

Authors: V. F. Azevedo, R. Pecoits-Filho

Published in: Rheumatology International | Issue 11/2010

Abstract

Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease characterized primarily by axial joint involvement, sacroiliitis and various extra-articular manifestations. High cardiovascular mortality in AS has led many researchers to investigate possible risk factors involved with cardiovascular disease in these patients. This review summarizes published data concerning endothelial dysfunction and atherosclerosis in patients with AS. The author discusses current limitations and problems related to a better assessment of these two possible changes in AS.

Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592CrossRefPubMed

Radford EP, Doll R, Smith PG (1977) Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 297:572–576CrossRefPubMed

Kaprove RE, Little AH, Graham DC et al (1980) Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 23:57–61CrossRefPubMed

Darby SC, Doll R, Gill SK et al (1987) Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. Br J Cancer 55:179–190PubMed

Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176CrossRefPubMed

Salmon JE, Roman MJ (2008) Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 121(10 Suppl 1):S3–S8CrossRefPubMed

Pereira IA, Borba EF (2008) The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 138(37–38):534–539

Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how ‘‘high-grade’’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963CrossRefPubMed

Ross R (1999) Atherosclerosis- an inflammatory disease. N Engl J Med 340:115–126CrossRefPubMed

10.

Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Ann Rev Immunol 22:361–403CrossRef

11.

Doria A, Sherer Y, Meroni PT, Schoenfeld Y (2005) Inflammation and accelerated atherosclerosis. Basic mechanisms. Rheum Dis N Am 31:355–362CrossRef

12.

Maksimowicz-McKinnon K, Bhatt DL, Calabrese LH (2004) Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol 16(1):18–24CrossRefPubMed

13.

Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75CrossRefPubMed

14.

Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed

15.

Sharrett AR, Ballantyne CM, Coady SA et al (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the atherosclerosis risk in communities (ARIC) study. Circulation 104:1108–1113CrossRefPubMed

16.

Rosenson RS (2005) Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Curr Opin Cardiol 20:313–317CrossRefPubMed

17.

Rader DJ (2002) High density lipoproteins and atherosclerosis. Am J Cardiol 90(suppl):i62–i70CrossRef

18.

Rossner S (1978) Further studies on serum lipoproteins in connective tissue diseases. Atherosclerosis 31:93–99CrossRefPubMed

19.

Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S (1984) High density lipoprotein cholesterol subfractions and apolipoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arhtritis Rheum 27:1199–2000CrossRef

20.

Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 109(2):171–176CrossRef

21.

Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26(5):710–714CrossRefPubMed

22.

van Halm VP, van Denderen JC, Peters MJ, Twisk JW, van der Paardt M, van der Horst-Bruinsma IE, van de Stadt RJ, de Koning MH, Dijkmans BA, Nurmohamed MT (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65(11):1473–1477CrossRefPubMed

23.

Masi AT, Aldag JC, Mohan PC, Murugan TSR (1999) Determinants of significantly lower serum total cholesterol levels in ankylosing spondylitis patients than age-, gender-, and medical service-matched control patients: results of multivariate analysis. Arthritis Rheum 42(Suppl):S300

24.

Masi AT, Aldag JC, Mohan PC, Murugan TSR (2000) Significantly lower serum triglyceride levels in ankylosing spondylitis patients than age-, gender-, and medical service-matched controls: results of multivariate analysis. Arthritis Rheum 43(Suppl):S104

25.

Burger D, Dayer JM (2002) High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? Autoimmun Rev 1:111–117CrossRefPubMed

26.

Hulthe J, Fagerberg B (2002) Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 22:1162–1167CrossRefPubMed

27.

Tabas I, Williams KJ, Borén J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Update and therapeutic implications. Circulation 116:1832–1844CrossRefPubMed

28.

Marcora S, Casanova F, Williams E et al (2006) Preliminary evidence for cachexia in patients with well established ankylosing spondylitis. Rheumatology (Oxford) 45:1385–1388CrossRef

29.

Engvall IL, Elkan AC, Tengstrand B, Cederholm T, Brismar K, Hafstrom I (2008) Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol 37(5):321–328CrossRefPubMed

30.

Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767–1772PubMed

31.

Luc G, Bard JM, Juhan-Vague I et al (2003) C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol 23:55–1261CrossRef

32.

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214CrossRefPubMed

33.

Pepine CJ (1998) Clinical implications of endothelial dysfunction. Clin Cardiol 21:795–799CrossRefPubMed

34.

Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115(10):1285–1295PubMed

35.

Ganz P, Vita JA (2003) Testing endothelial vasomotor function. Nitric oxide, a multipotent molecule. Circulation 108:2049–2053CrossRefPubMed

36.

Landmesser U, Hornig B, Drexler H (2004) Endothelial function: a critical determinant in atherosclerosis? Circulation 109(suppl II):II-27–II-33CrossRef

37.

Widlansky ME, Gokce NL, Keaney JF Jr, Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149–1160CrossRefPubMed

38.

Langheinrich AC, Kampschulte M, Buch T, Bohle RM (2007) Vasa vasorum and atherosclerosis—Quid novi? Thromb Haemost 97(6):873–879PubMed

39.

Amoroso A, Del Porto F, Di Monaco C, Manfredini P, Afeltra A (1997) Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review. Eur Rev Med Pharmacol Sci 1:17–25PubMed

40.

Ballara SC, Miotla JM, Paleolog EM (1999) New vessels, new approaches:angiogenesis as a therapeutic target in musculoskeletal disorders. Int J Exp Pathol 80:235–250CrossRefPubMed

41.

Benjamin M, Toumi H, Suzuki D, Hayashi K, McGonagle D (2008) Evidence for a distinctive pattern of bone formation in enthesophytes. Ann Rheum Dis. 2008 Jul 14. [Epub ahead of print]

42.

Goldberger C, Dulak J, Duftner C, Weidinger F, Falkenbach A, Schirmer M (2002) Vascular endothelial growth factor (VEGF) in ankylosing spondylitis–a pilot study. Wien Med Wochenschr 152(9–10):223–225CrossRefPubMed

43.

Drouart M, Saas P, Billot M, Cedoz J-P, Tiberghien P, Wendling D, Toussirot É (2003) High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132:158–162CrossRefPubMed

44.

Taylor HG, Weiss JB, McLaughlin B, Dawes PT (1993) Raised endothelial cell stimulating angiogenesis factor in ankylosing spondylitis. Clin Exp Rheumatol 11(5):537–539PubMed

45.

Jones PB, Makki RJ, Weiss JB (1994) Endothelial cell stimulating angiogenesis factor–a new biological marker for disease activity in ankylosing spondylitis? Br J Rheumatol 33(4):332–335CrossRefPubMed

46.

Karoli NA, Rebrov AP (2007) Vascular wall lesion and disorder of endothelial vasoregulating function in patients with ankylosing spondylitis. Klin Med (Mosk) 85(6):54–57

47.

Poddubnyĭ DA, Rebrov AP (2007) Endothelial dysfunction in patients with Bechterew’s disease (ankylosing spondylitis). Klin Med (Mosk) 85(7):66–69

48.

George F, Brisson C, Poncelet P, Laurent JC, Massot O, Arnoux D, Ambrosi P, Klein-Soyer C, Cazenave JP, Sampol J (1992) Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 67:147–153PubMed

49.

Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R et al (2002) Anti-tumournecrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 61(Suppl 3):iii51–iii60PubMed

50.

Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J et al (1994) Serum cytokines(IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a closecorrelation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931CrossRefPubMed

51.

Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation ofnitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736):601–605CrossRefPubMed

52.

Caliskan M, Erdogan D, Gullu H, Yilmaz S, Gursoy Y, Yildirir A et al (2008) Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 196(1):306–312CrossRefPubMed

53.

Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75(5):548–553CrossRefPubMed

54.

de Jongh RT, Ijzerman RG, Serne EH, Voordouw JJ, Yudkin JS, de Waal HA et al (2006) Visceral and truncal subcutaneous adipose tissue are associated with impaired capillaryrecruitment in healthy individuals. J Clin Endocrinol Metab 91(12):5100–5106CrossRefPubMed

55.

Ijzerman RG, Voordouw JJ, van Weissenbruch MM, Yudkin JS, Serne EH, Delemarrevande Waal HA et al (2006) TNF-alpha levels are associated with skin capillary recruitment in humans: a potential explanation for the relationship between TNF-alpha and insulin resistance. Clin Sci (Lond) 110(3):361–368CrossRef

56.

Wofford J, Kahl F, Howard G, McKinney W, Toole J, Crouse JI (1991) Relation of extent of extracranial carotid artery atherosclerosis as measured by B-mode ultrasound to the extent of coronary atherosclerosis. Arterioscler Thromb 11(6):1786–1794PubMed

57.

Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45:283–286CrossRefPubMed

58.

Mathieu S, Joly H, Baron G, Tournadre A, Dubost J-J, Ristori J-M, Lusson J-R, Soubrier M (2008) Trend towards increased arterial stiffness or intima–media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 47:1203–1207CrossRefPubMed

59.

Pieringer H (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 45(10):1319; author reply 1319–20. Comment on:Rheumatology (Oxford). 2006 Mar;45(3):283–286

60.

Galderisi M, Cicala S, Caso P et al (2002) Coronary flow reserve andmyocardial diastolic dysfunction in arterial hypertension. AmJ Cardiol 90:860–864CrossRef

61.

Erdogan D, Gullu H, Caliskan M et al (2005) Coronary flow reserve in dipper and non-dipper hypertensive patients. Blood Press 14:345–352CrossRefPubMed

62.

van Eijk IC, Peters MJL, Serne EH, van der Horst-Bruinsma IE, Dijkmans BAC, Smulders YM, Nurmohamed MT (2008) Microvascular function is impaired in ankylosing spondylitis and improves after TNF blockade. Ann Rheum Dis 2008 Apr 4. [Epub ahead of print]

63.

Braun J, Davis J, Dougados M, Sieper J, van der LS, van der HD (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316–320CrossRefPubMed

64.

Rudwaleit M, Listing J, Marker-Hermann E et al (2004) Spinal mobility in early ankylosing spondylitis and in axial SpA without definite radiographic sacroillitis. Ann Rheum Dis 63(Suppl 1):400

Title: Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis
Authors: V. F. Azevedo
R. Pecoits-Filho
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 11/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1416-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2010

Relative importance of the functional abilities comprising Health Assessment Questionnaire Disability Index among rheumatoid arthritis patients

Thoracic outlet syndrome due to an axillary band: what if it ruptures?

Assessment of latent tuberculosis infection in Takayasu arteritis with tuberculin skin test and Quantiferon-TB Gold test

IL-23 and IL-17 in ankylosing spondylitis

Fibromyalgia and nutrition, what do we know?

Lupus or tuberculosis: which comes first?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials